5-MTHF Acid Formulation in Cardiovascular Homocysteine-Lowering Blends
Thermal Degradation Thresholds of 5-MTHF Acid During Twin-Screw Extrusion: Barrel Temperature Zoning and Screw Speed Parameters for Chewable Tablet Production
When formulating chewable tablets containing 5-MTHF acid for cardiovascular homocysteine-lowering blends, thermal processing is a critical factor. Twin-screw extrusion, often used for granulation, exposes the active to elevated temperatures. Our field experience indicates that 5-MTHF acid begins to show noticeable degradation above 80°C, with rapid decomposition occurring beyond 120°C. To preserve potency, barrel temperature zoning should be set with a feed zone at 25–30°C, a mixing zone not exceeding 60°C, and a die zone below 70°C. Screw speeds of 150–200 rpm minimize residence time while ensuring uniform mixing. We have observed that the free acid form is more thermally labile than certain salt forms, such as the calcium salt of L-5-Methyltetrahydrofolate, which can withstand slightly higher temperatures. For chewable tablets, a direct compression approach using pre-granulated 5-MTHF acid with suitable excipients often yields better stability. As a drop-in replacement for other methylfolate sources, our 5-MTHF acid maintains identical performance when these thermal limits are respected. For detailed formulation guidance, refer to our article on 5-Mthf Equivalente A Magnafolate® Tipo C Para Suplementos Líquidos, which discusses liquid supplement applications.
Purity Grades and COA Specifications for 5-MTHF Acid in Cardiovascular Homocysteine-Lowering Blends: Ensuring Potency and Stability
For cardiovascular blends targeting homocysteine reduction, the purity of 5-MTHF acid is paramount. Our product, 5-Methyltetrahydrofolic Acid (CAS 134-35-0), is manufactured under GMP certified conditions and typically achieves a purity of >98% by HPLC. The Certificate of Analysis (COA) includes assay, water content, residual solvents, and heavy metals. A critical specification is the diastereomeric purity: the biologically active 6[S] isomer should be >99%, with minimal 6[R] content. This is essential because the non-natural 6[R] isomer may accumulate in tissues, as noted in pharmacokinetic studies. Our COA also reports the calcium content if the product is provided as a calcium salt, but for the free acid form, we ensure low calcium levels to avoid interference in formulations. The table below compares typical specifications for our 5-MTHF acid versus a common competitor equivalent.
| Parameter | Our 5-MTHF Acid | Competitor Equivalent |
|---|---|---|
| Assay (HPLC, anhydrous basis) | 98.0–102.0% | 97.0–102.0% |
| Water Content (Karl Fischer) | ≤ 8.0% | ≤ 8.0% |
| 6[S] Isomer Purity | ≥ 99.5% | ≥ 99.0% |
| Residual Solvents | USP <467> compliant | USP <467> compliant |
| Heavy Metals | ≤ 10 ppm | ≤ 20 ppm |
Please refer to the batch-specific COA for exact values. Our commitment to high purity ensures that your cardiovascular blends deliver consistent efficacy. For insights into how our product compares to Magnafolate® in liquid supplements, see 5-Mthf Equivalente A Magnafolate® Tipo C Para Suplementos Líquidos.
Bulk Packaging and Handling of 5-MTHF Acid: IBC and Drum Solutions for Industrial Formulation
For industrial-scale formulation of cardiovascular blends, we supply 5-MTHF acid in standard bulk packaging: 25 kg fiber drums with double PE liners, or 500 kg IBC totes for larger volumes. The material is hygroscopic and oxygen-sensitive, so packaging includes nitrogen flushing and desiccant bags. Storage recommendations are 2–8°C in a dry, dark environment. When handling, avoid dust generation and use local exhaust ventilation. Our logistics team ensures secure transport with temperature monitoring upon request. As a global manufacturer, we maintain ample stock to support just-in-time delivery, making us a reliable drop-in replacement for your current methylfolate source.
Non-Standard Parameter: Viscosity Shifts and Crystallization Behavior of 5-MTHF Acid Under Sub-Zero Storage Conditions
While standard storage is at 2–8°C, some formulators may encounter sub-zero temperatures during transport or storage. Our field experience reveals that 5-MTHF acid, when in solution, exhibits a significant viscosity increase below -5°C, and may form needle-like crystals if the solution is not properly buffered. This crystallization can lead to inhomogeneity in liquid blends. To mitigate this, we recommend using a citrate or phosphate buffer system to maintain pH 6.5–7.0, which reduces the risk of precipitation. For solid forms, the free acid remains amorphous but can absorb moisture if packaging is compromised, leading to clumping. These non-standard parameters are critical for formulators working in cold climates or with refrigerated supply chains.
Drop-in Replacement Strategy: Cost-Efficiency and Supply Chain Reliability of Our 5-MTHF Acid Versus Competitor Equivalents
Our 5-MTHF acid is designed as a seamless drop-in replacement for other methylfolate sources like Metafolin® or Magnafolate®. With identical technical parameters—including 6[S] isomer purity, solubility, and bioavailability—you can substitute our product without reformulation. The key advantages are cost-efficiency and supply chain reliability. By sourcing directly from our GMP certified facility, you eliminate distributor markups and reduce lead times. We offer competitive bulk pricing and flexible contract terms. Our global logistics network ensures consistent delivery, avoiding the stockouts that plague single-source suppliers. For cardiovascular homocysteine-lowering blends, our 5-MTHF acid provides the same clinical benefits at a lower total cost of ownership.
Frequently Asked Questions
How does the thermal stability of 5-MTHF free acid compare to its calcium salt form under high-shear mixing conditions?
Under high-shear mixing, the free acid form of 5-MTHF is more susceptible to thermal degradation than the calcium salt. The calcium salt, such as L-5-Methyltetrahydrofolate calcium, can tolerate temperatures up to 90°C for short periods, while the free acid begins to degrade above 70°C. For processes involving high-shear mixing that generate significant heat, we recommend using the calcium salt or implementing cooling jackets to maintain the product temperature below 60°C. Alternatively, consider a low-shear granulation method or direct compression to minimize thermal stress.
What alternative processing routes can be used if the free acid form is unstable in my current formulation?
If the free acid form of 5-MTHF proves unstable in your formulation, consider switching to a more stable salt form such as the calcium or glucosamine salt. These salts offer improved thermal and oxidative stability. Another approach is to use microencapsulation techniques to protect the active during processing. For liquid formulations, using a buffered system at pH 6.5–7.0 with antioxidants like ascorbic acid can enhance stability. Our technical team can provide guidance on selecting the optimal form for your specific process.
Sourcing and Technical Support
As a leading global manufacturer of 5-Methyltetrahydrofolic Acid, NINGBO INNO PHARMCHEM CO.,LTD. offers comprehensive technical support from R&D to scale-up. Our experts can assist with formulation challenges, stability studies, and regulatory documentation. We invite you to explore our product page for detailed specifications: high-purity 5-Methyltetrahydrofolic Acid for cardiovascular blends. Partner with a verified manufacturer. Connect with our procurement specialists to lock in your supply agreements.